Clinical Trials Logo

Gynecological Malignancies clinical trials

View clinical trials related to Gynecological Malignancies.

Filter by:
  • None
  • Page 1

NCT ID: NCT06151028 Recruiting - Bone Loss Clinical Trials

An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy

Start date: December 1, 2023
Phase:
Study type: Observational

Through long-term dynamic monitoring of gynecologic malignant tumor patients undergoing early menopause after ovaries resection in our center, we explored the changes in menopausal symptoms and bone health status of this population, and studied the effects of platinum combined chemotherapy drugs on menopausal symptoms and bone loss in gynecologic malignant tumor patients. To find the optimal time point and effective regimen for MHT in gynecologic malignancies undergoing surgical menopause, and to provide guidance for osteoporosis screening and prevention strategies in women with gynecologic cancer.

NCT ID: NCT06131450 Recruiting - Clinical trials for Gynecological Malignancies

A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Start date: February 29, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with HER2-expressing recurrent or metastatic gynecologic malignancies.

NCT ID: NCT05914974 Recruiting - Ovarian Cancer Clinical Trials

Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies

Start date: September 11, 2023
Phase:
Study type: Observational

ICK-Gyn is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in advanced or metastatic gynecological malignancies under immune checkpoint inhibitor (ICI) therapy on the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS).

NCT ID: NCT04905329 Recruiting - Breast Cancer Clinical Trials

A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Def_Special
Start date: April 28, 2020
Phase:
Study type: Observational

This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with High and "Gray Zone" Risk Reccurrence Breast Cancer, Gastointestinal Cancers and Gynecological Malignancies

NCT ID: NCT02718209 Not yet recruiting - Clinical trials for Gynecological Malignancies

The Development of an In-vitro System to Identify Gynecologic Cancer Cells During Surgical Procedures

Start date: April 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the efficacy of mid-infrared spectroscopy together with Attenuated Total Reflection (ATR), for the detection of gynecological malignancies in real time during surgery.

NCT ID: NCT00770536 Completed - Cancer Clinical Trials

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer. Up to 100 subjects will be enrolled to receive AMG 386 in combination with either pegylated liposomal doxorubicin every 4 weeks (cohort A) or topotecan weekly on days 1, 8, and 15 of a 28 day dosing schedule (cohort B). Subject enrollment and assignment to either cohort will be based on eligibility and the investigator's discretion. It is hypothesized that AMG 386, in combination with each of the chemotherapy regimens: either pegylated liposomal doxorubicin or topotecan will be safe and well tolerated in subjects with recurrent ovarian cancer.

NCT ID: NCT00121030 Completed - Anemia Clinical Trials

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

Start date: October 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in gynecological cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.